Neurocrine Biosciences (NBIX) Change in Inventory (2017 - 2026)

Neurocrine Biosciences has reported Change in Inventory for 10 years, with the latest figure at -$4.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Inventory fell 352.94% year-over-year to -$4.3 million; the trailing twelve-month figure through Mar 2026 stood at $9.3 million (down 57.53% YoY), and the FY2025 full-year result was $15.3 million, down 19.9% from the prior year.
• Change in Inventory for Q1 2026 stood at -$4.3 million, down from $3.4 million in the prior quarter.
• The five-year high for Change in Inventory was $12.3 million in Q3 2025, with the low at -$4.3 million in Q1 2026.
• Historically, Change in Inventory has averaged $1.6 million across 5 years, with a median of $300000.0 in 2022.
• Annual changes were most pronounced in 2023 — Change in Inventory plunged 633.33% — and 2024, when it jumped 1188.89%.
• Neurocrine Biosciences' Change in Inventory stood at -$3.9 million in 2022, then soared by 123.08% to $900000.0 in 2023, then jumped by 1188.89% to $11.6 million in 2024, then slumped by 70.69% to $3.4 million in 2025, then plunged by 226.47% to -$4.3 million in 2026.
• The last three Change in Inventory figures came in at -$4.3 million (Q1 2026), $3.4 million (Q4 2025), and $12.3 million (Q3 2025), per Business Quant data.